APPROVED: Durata's Dalvance 1st 'QIDP' antibiotic OK'd for US market
This article was originally published in Scrip
Executive Summary
The FDA on 23 May granted Durata Therapeutics approval to market its antibiotic Dalvance (dalbavancin) as treatment for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).